Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS

$125m Upfront For InnoCare

BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.

Biogen
Biogen wants to stay competitive in MS, and sees BTK inhibitors a potentially key to the field's future. • Source: Alamy

Biogen has paid $125m upfront to get its hands on Chinese company InnoCare’s orelabrutinib, one of a number of promising BTK inhibitors which could transform multiple sclerosis (MS) treatment.

While Biogen is in the news for the ongoing controversy around its newly approved Alzheimer’s drug Aduhelm (aducanumab), it is...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip